Aeglea BioTherapeutics to Present at the 2017 Wells Fargo Healthcare Conference
August 31 2017 - 4:05PM
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company
committed to developing enzyme-based therapeutics in the field of
amino acid metabolism to treat rare genetic diseases and cancer,
today announced that management will be presenting at the 2017
Wells Fargo Healthcare Conference in Boston on Wednesday,
September 6 at 8:30 a.m. ET.
To access the live and archived webcast of the presentation,
please visit the Investor Relations section of the Aeglea
BioTherapeutics website. The webcast and presentation will be
archived for viewing for 60 days thereafter.
About Aeglea BioTherapeuticsAeglea is a
biotechnology company committed to developing enzyme-based
therapeutics in the field of amino acid metabolism to treat rare
genetic diseases and cancer. The company’s engineered human enzymes
are designed to modulate the extremes of amino acid metabolism in
the blood to reduce toxic levels of amino acids in inborn errors of
metabolism or target tumor metabolism for cancer treatment.
AEB1102, Aeglea’s lead product candidate, is currently being
studied in two ongoing Phase 1 clinical trials in patients with
advanced solid tumors and acute myeloid leukemia/myelodysplastic
syndrome (AML/MDS). Additionally, Aeglea is recruiting patients
into its ongoing Phase 1/2 trial of AEB1102 for the treatment of
patients with Arginase 1 Deficiency. The company is building a
pipeline of additional product candidates targeting key amino
acids, including AEB4104, which degrades homocystine, a target for
an inborn error of metabolism, as well as two potential treatments
for cancer, AEB3103, which degrades cysteine, and its oxidized form
cystine, and AEB2109, which degrades methionine.
For more information, please
visit http://aegleabio.com.
Media Contact:
Kelly Boothe, Ph.D.
Pure Communications
415.946.1076
media@aegleabio.com
Investor Contact:
Charles N. York II
Chief Financial Officer
Aeglea BioTherapeutics
investors@aegleabio.com
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Apr 2023 to Apr 2024